<DOC>
	<DOCNO>NCT01343719</DOCNO>
	<brief_summary>The objective current study investigate safety , tolerability , pharmacokinetics treatment BI 661051 rise single dos administer oral drinking solution ( powder bottle ) healthy male subject . The primary objective investigate safety tolerability treatment BI 661051 . The secondary objective ( 1 ) evaluate single dose pharmacokinetics BI 661051 , ( 2 ) explore dose proportionality , ( 3 ) explore relative bioavailability BI 661051 administer tablet two dose level compare oral drinking solution ( 4 ) ass effect bioavailability BI 661051 administer oral drinking solution intake high fat meal . Pharmacodynamic parameter determine within study .</brief_summary>
	<brief_title>Single Rising Dose Study Assess Safety , Tolerability Pharmacokinetics BI 661051 .</brief_title>
	<detailed_description>Purpose :</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Inclusion criterion : 1 . Healthy male base upon complete medical history , include physical examination , vital sign ( blood pressure ( BP ) , pulse rate ( PR ) ) , 12lead electrocardiogram ( ECG ) , clinical laboratory test . There find deviate normal clinical relevance . There evidence clinically relevant concomitant disease . 2 . Age =18 age =50 year . 3 . BMI =18.5 BMI =30 kg/m2 ( Body Mass Index ) . 4 . Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation . Exclusion criterion : 1 . Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance . 2 . Any evidence clinically relevant concomitant disease . 3 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder . 4 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder . 5 . History relevant orthostatic hypotension , faint spell blackout . 6 . Chronic relevant acute infection . 7 . History relevant allergy/hypersensitivity ( include allergy drug excipients ) judge clinically relevant investigator . 8 . Intake drug long halflife ( &gt; 24 h ) within least 1 month less 10 halflives respective drug prior administration . 9 . Use drug might reasonably influence result trial base knowledge time protocol preparation within 10 day prior randomisation . 10 . Participation another trial investigational drug within 30 day prior randomisation . 11 . Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) . 12 . Inability refrain smoke trial day judge investigator . 13 . Alcohol abuse ( 30 g/day ) . 14 . Drug abuse . 15 . Blood donation ( 100 mL within 4 week prior randomisation trial ) . 16 . Excessive physical activity ( within 1 week prior randomisation trial ) . 17 . Any laboratory value outside reference range clinical relevance . 18 . Inability comply dietary regimen study centre .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>